Please login to the form below

Not currently logged in
Email:
Password:

Linda Law joins Advicenne as US VP, clinical development and med affairs

She will oversee the biopharma’s developments with its dTRA candidate

Linda Late-stage biopharmaceutical company Advicenne has appointed Linda Law as its new US vice president of clinical development and medical affairs.

Law will take responsibility for the group’s efforts in North America, which are focused on its distal Renal Acidosis (dTRA) candidate and she will report to Advicenne’s chief executive officer Dr Luc-André Granier.

She brings 20 years’ of experience in international pharmaceutical development and medical affairs across a range of therapeutic areas to the group.

Commenting on her appointment, Granier said: “This is a pivotal time for Advicenne and Dr Law’s experience and deep knowledge of US clinical development will be of great value of Advicenne.

“Her appointment also marks the start of the company’s US operations.”

Law’s career has seen her serve in various positions for pharmaceutical companies including Procter & Gamble, Lexicon Pharmaceuticals and she has consulted on evaluation and development projects with Takeda, Confluence and Forest Pharmaceuticals.

1st February 2018

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...